<DOC>
	<DOC>NCT00241137</DOC>
	<brief_summary>The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives</brief_summary>
	<brief_title>A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>â€¢ Male or female age between 1880 years of age, inclusive Diagnosed at enrollment (visits 2) to be mild to moderate hypertensive with a MSDBP &gt;= 95 and =&lt; 109 mmHg for non treated patients. Previously treated patients should have a MSDBP =&lt; 109 mmHg at visit 1 and a MSDBP &gt;= 95 and =&lt; 109 mmHg at visit 2. Written informed consent to participate in the study prior to any study procedures Ability to communicate and comply with all study requirements Severe hypertension (grade 3 of WHO classification; &gt;= 110 mmHg diastolic and/or &gt;= 180 mmHg systolic). Malignant hypertension Inability to discontinue all prior antihypertensive medications safely for a period of 2 weeks, as required by the protocol. Known history of proteinuria (greater than 0.3 gram per day) Female patients who are not either postmenopausal for one year or surgically sterile, and who are not using effective contraceptive methods such as barrier method with spermicidal or an intrauterine device. Oral contraceptive use is not allowed. Known KeithWagener grade III or IV hypertensive retinopathy. History of hypertensive encephalopathy or cerebrovascular accident at anytime prior to Visit 1. Transient ischemic cerebral attack during the last 12 months prior to Visit 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
</DOC>